OncoMed Pharmaceuticals Inc
DelistedCIK 1302573fmd_1CR9A5ZB5HXE0G26H2W4XYRYREManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Dec 31, 2018, 29 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 31 | 25 | 38 | 40 | 26 | 25 | 38 | 44 |
| Research and development | 40 | 40 | 50 | 76 | 93 | 110 | 60 | 34 |
| Total operating expenses | 47 | 47 | 62 | 90 | 111 | 129 | 79 | 54 |
| Operating income | (15) | (22) | (24) | (51) | (86) | (103) | (41) | (10) |
| Interest expense | 0 | 0 | – | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | 0 | 1 | 2 |
| Income before taxes | (15) | (22) | (24) | (51) | (85) | (103) | (40) | (8) |
| Income tax expense | – | 0 | 2 | (1) | 0 | 0 | (1) | (0) |
| Net income from continuing operations | – | (22) | (26) | (50) | (85) | (103) | (39) | (8) |
| Net income | (15) | (22) | (26) | (50) | (85) | (103) | (39) | (8) |